Thelma Therapeutics (XKRX:015540) EV-to-EBIT : 405.68 (As of Jun. 07, 2024)

Thelma Therapeutics EV-to-EBIT Chart

Thelma Therapeutics Annual Data
	Trend	Dec12	Dec13	Dec14	Dec15	Dec16	Dec17	Dec18	Dec19	Dec20	Dec21
EV-to-EBIT		Get a 7-Day Free Trial					-4.65	-4.45	-2.46	-10.06	-50.73

Thelma Therapeutics Quarterly Data
	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
EV-to-EBIT	Get a 7-Day Free Trial															-12.42	-50.73	-58.99	5,918.71	793.90

Competitive Comparison of Thelma Therapeutics's EV-to-EBIT

For the Specialty Business Services subindustry, Thelma Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Thelma Therapeutics's EV-to-EBIT Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Thelma Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Thelma Therapeutics's EV-to-EBIT falls into.

Thelma Therapeutics EV-to-EBIT Calculation

Thelma Therapeutics's EV-to-EBIT for today is calculated as:

Thelma Therapeutics's current Enterprise Value is ₩86,229 Mil.
Thelma Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩213 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thelma Therapeutics  (XKRX:015540) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Thelma Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2022 is calculated as:

Thelma Therapeutics's Enterprise Value for the quarter that ended in Sep. 2022 was ₩168,748 Mil.
Thelma Therapeutics's EBIT for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩213 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Thelma Therapeutics EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Thelma Therapeutics's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Thelma Therapeutics (XKRX:015540) Business Description